Responses
Regular and young investigator award abstracts
Clinical trials in progress
385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results
Compose a Response to This Article
Other responses
No responses have been published for this article.